New England Journal of Medicine· 2021Q1
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
- 2,658citations
- Q1SCImago
- 2021year
Short summary
Adding lutetium-177–PSMA-617 (Lu-PSMA-617) to standard care significantly improved progression-free survival (PFS) and overall survival (OS) in patients with PSMA-positive metastatic castration-resistant prostate cancer.
AI-generated from the title and abstract; the full text is not read.
Key points
- Lu-PSMA-617 added to standard care reduced the risk of death by 38% (hazard ratio [HR], 0.62) and radiographic progression or death by 60% (HR, 0.40) compared to standard care alone.
- Objective response rates were 29.8% in the Lu-PSMA-617 group versus 2.2% in the standard care group.
- Median imaging-based progression-free survival was 8.7 months with Lu-PSMA-617 versus 3.4 months without.
- Median overall survival was 15.3 months with Lu-PSMA-617 versus 11.3 months without.
- Quality of life was not adversely affected by the addition of Lu-PSMA-617.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: Lu)-PSMA-617 is a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment. METHODS: Ra), and investigational drugs. The alternate primary end points were imaging-based progression-free survival and overall survival, which were powered for hazard ratios of 0.67 and 0.73, respectively. Key secondary end points were objective response, disease control, and time to symptomatic skeletal events. Adverse events during treatment were those occurring no more than 30 days after the last dose and before subsequent anticancer treatment. RESULTS: Lu-PSMA-617 than without (52.7% vs. 38.0%), but quality of life was not adversely affected. CONCLUSIONS: Lu-PSMA-617 prolonged imaging-based progression-free survival and overall survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. (Funded by Endocyte, a Novartis company; VISION ClinicalTrials.gov number, NCT03511664.).
The authors' abstract, as published at the source. New England Journal of Medicine, 2021 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pulmonary and Respiratory Medicine
Pulmonary and Respiratory MedicineMedicine